Besides, no cohort study has ever been published on this subject due to the limited population of HER2 positive stage IV gastric cancer (amplification or overexpression of HER 2 is observed in only 7–34% of gastric cancer [8–10]. This evidence concerns the gene ERBB2 and gastric cancer.